Quinn Opportunity Partners’s Cytokinetics CYTK Stock Holding History

Quinn Opportunity Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$426K	Sell	5,000 -11,000	-69%	-$790K	0.02%	286
2026 Q1	$1.05M	Sell	16,000 -22,082	-58%	-$1.4M	0.06%	207
2025 Q4	$2.42M	Sell	38,082 -235,579	-86%	-$14.7M	0.1%	163
2025 Q3	$15M	Buy	273,661 +78,722	+40%	+$3.24M	1.07%	15
2025 Q2	$6.44M	Buy	194,939 +65,000	+50%	+$2.26M	0.54%	52
2025 Q1	$5.22M	Buy	129,939 +14,000	+12%	+$643K	0.36%	80
2024 Q4	$5.45M	Buy	115,939 +9,302	+9%	+$483K	0.37%	73
2024 Q3	$5.63M	Buy	106,637 +16,000	+18%	+$892K	0.54%	49
2024 Q2	$4.91M	Buy	90,637 +44,260	+95%	+$2.67M	0.56%	50
2024 Q1	$3.25M	Buy	46,377 +38,377	+480%	+$2.97M	0.36%	74
2023 Q4	$668K	Buy	+8,000	New	+$290K	0.07%	140

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quinn Opportunity Partners's CYTK Position: Q2 2026 in Review

Quinn Opportunity Partners reduced its Cytokinetics (CYTK) stake by 69% in Q2 2026, selling an estimated $790K and leaving 5,000 shares worth $426K. The position accounts for 0.02% of the portfolio, ranked #286.

Quinn Opportunity Partners first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. The position peaked at $15M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Quinn Opportunity Partners held 5,000 shares of Cytokinetics worth $426K as of Q2 2026.
Quinn Opportunity Partners sold 11,000 Cytokinetics shares in Q2 2026, an estimated $790K.
Cytokinetics made up 0.02% of Quinn Opportunity Partners's portfolio in Q2 2026, its #286 holding.
Quinn Opportunity Partners first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
Quinn Opportunity Partners's Cytokinetics position peaked at $15M in Q3 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.